Aculys Pharma, Inc., a Japan-based clinical-stage biopharmaceutical company, announced on Monday that it has named Hidemasa Tanigaki as its new executive officer and representative director.

Hidemasa started his career with Takeda Pharmaceutical Company and served in various key positions throughout his tenure with the company. He joined the company as a medical rep and later served as global lead in Boston for the oncology business strategy. He has also worked as sales director for Specialty Pharma and the head of Rare Hematology, prior to assuming the role of president and representative director of Nihon Pharmaceutical Co., Ltd. He then headed the Gastrointestinal Disease Business Unit at Takeda.

BT Slingsby, executive chairperson of Aculys, said, 'The Aculys board warmly welcomes Hidemasa as the new CEO of Aculys. We believe his impressive track record and experience in the pharmaceutical sector make him an ideal leader to take the team and assets toward commercialisation. We are confident he will continue to position the Company as a leading biopharma in the field of neurological and psychiatric disorders, executing Aculys' clinical, commercial, and financial strategy.'